pharmaceutical industry
The latest news about pharmaceutical industry: headlines, AI summaries and the full story from every source.
- Democratic Lawmakers Plan Investigation Into Trump Administration Drug Pricing Deals
- Revenue Comparison: Eli Lilly's GLP-1 Growth vs. Bristol Myers Squibb's Steady Performance
- Moderna Added to Nasdaq-100 Index, Impact on Investors
- FTC and Seven States Seek Contempt Action Against Martin Shkreli for Alleged Violation of Pharma Industry Ban
- PhRMA Sues Trump Administration Over Most-Favored-Nation Drug Pricing Policy
- Pfizer Announces $0.43 Quarterly Dividend
- Novo Nordisk Rebrands as Novo to Strengthen Consumer Appeal
- Pfizer Stock Surges Nearly 14% in August Due to Strong Earnings and Regulatory Advances
- AstraZeneca Leads Pharma Growth While Bristol Myers Trails Amid Merger Rumors
- AstraZeneca and Bristol Myers Squibb Held Merger Talks
- AstraZeneca Q2 Earnings Beat on Strong Cancer Drug Sales
- Trump Administration Reaches Drug-Pricing Agreements with Major Pharma Firms Including Pfizer and AbbVie
- Biopharma Industry Confidence Reaches Four-Year High Despite Geopolitical Challenges
- Veeva Systems Announces Kindeva is Adopting Veeva Quality Cloud
- Lantheus Considering Potential $7 Billion Sale Following Curium's Takeover Offer
- Travere Therapeutics Reports Q2 2025 Earnings with Strong Sales Growth
- Eli Lilly's GLP-1 Drugs Drive Revenue Growth, With Potential for Further Expansion
- Class Action Settlement Announced for QVAR® and QVAR RediHaler® Inhalers
- Eli Lilly Reports Strong Q1 2026 Earnings, Raised Guidance Due to Mounjaro and Zepbound Sales
- Big Pharma M&A Activity Surges in 2026 Due to Patent Expiries and Strategic Acquisitions
- Pomerantz Law Firm Investigates Theravance Biopharma for Potential Securities Fraud
- Bristol Myers Squibb Reports Strong First-Quarter Results, Driving Stock Higher
- Merck Reports Q1 2026 Earnings with Revenue Growth and Product Performance Highlights
- Eli Lilly Reports Strong Q1 Results, Shares Rise on Beat-and-Raise
- Bristol Myers Squibb Reports Q1 2026 Earnings with Mixed Revenue Performance
- Goldman Sachs Lowers Pfizer's Price Target Ahead of Earnings Report
- Verified Clinical Trials and Chubb Announce Strategic Alliance to Enhance Clinical Trial Safety and Data Quality
- Alnylam Pharmaceuticals Reports Strong First-Quarter Sales for Amvuttra
- Pinnaql Acquires Pharma Resource Group to Expand Scientific and Manufacturing Advisory Services
- Verified Clinical Trials and Chubb Announce Strategic Alliance to Improve Clinical Trial Safety and Data Quality
- Guggenheim Increases Price Target for Eli Lilly Amid Acquisition Activity
- Novartis Q1 Sales Decline Reflects Industry Challenges with Generics and Patent Expirations
- Organon & Co. (OGN) Reaches 52-Week High Following $11.75-Billion Merger with Sun Pharmaceuticals
- UK's Largest Drugmakers Report Higher Than Expected Profits Amid U.S. Pricing Policy Concerns
- Novartis Reports Weaker Q1 Results Due to Generic Competition
- Novartis Reports Missed Q1 Estimates, Reaffirms Full-Year 2026 Guidance
- Novo Nordisk Partners with OpenAI to Accelerate Drug Development
- Sun Pharma Acquires Organon in $11.75 Billion Deal
- MFN Policy Impact on Pharmaceutical Launches in Nordic Countries
- Johnson & Johnson Uses AI to Halve Drug Development Lead Time
- GSK Subsidiary Tesaro and AnaptysBio Update on Contract Litigation
- Sun Pharma Acquires Organon in $11.75 Billion Deal
- Sun Pharma Agrees to Acquire Organon in $12 Billion Deal
- Sun Pharma Acquires Organon for $11.75 Billion
- Sun Pharma Agrees to $11.8 Billion Acquisition of Organon
- GSK Subsidiary TESARO Dismisses AnaptysBio's Anticipatory Breach Claim
- Indian drugmaker Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal
- Sun Pharma Increases Takeover Bid for Organon to $13 Billion, Driving Share Price Up 30.9%
- Eton Pharmaceuticals Appoints Judith M. Matthews as New CFO
- Pfizer's Dividend Yield Rises to 6.3% Amid Concerns Over Future Prospects